Published in Vaccine Weekly, June 14th, 1999
RSV is the leading viral cause of major pediatric respiratory illness. A promising attenuated live-virus RSV vaccine is now in clinical trials, but development of subunit vaccines - needed to boost immunity in elderly populations and for safe vaccination of immunocompromised populations - lags behind.
Now it appears clear why a subunit vaccine has been so hard to create: RSV has evolved a means of evading the immune system. The immunodominant epitope in the viral envelope matures by going through...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.